These studies are highly significant and clinically relevant to understand the emergence of drug resistance; addition of Dasatinib to Docetaxel, a cytotoxic chemotherapy drug targeting microtubules, did not improve the overall survival in Phase 3 trials for chemotherapy-naive men with metastatic CRPC 33 .
← all excerpts
Blockade of ACK1/TNK2 To Squelch the Survival of Prostate Cancer Stem-like Cells.
1
—
—